Later genomic events may alternatively reflect subclonal outgrowth resulting from therapeutic bottlenecks during CLL treatment [26], such as the selection and expansion of small TP53-mutated subclones that carry similar prognostic impact to clonal TP53 aberrations [24,28]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.